arrow
M

Michelle Krogsgaard

NYU Grossman School of Medicine
H指数:33
被引数:5,226

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Natalizumab and fumarate treatment differentially modulate CD4+ T cell and B cell subtypes in multiple sclerosis patients without impacting durable COVID-19 vaccine responses

Natalizumab和fumarate治疗以不同的方式调节多发性硬化患者中的CD4+ T细胞和B细胞亚型,而不会影响持久的COVID-19疫苗应答。

2025-11-190
OAAI
Longitudinal study of immunity to SARS-CoV2 in ocrelizumab-treated MS patients up to 2 years after COVID-19 vaccination
2024-05-071
OA
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy)

黑色素瘤的观点: 黑色素瘤桥会议报告 (2022年12月1至3日-意大利那不勒斯)

2023-07-282
OAAI
Molecular mechanism of phosphopeptide neoantigen immunogenicity (vol 14, 3763, 2023)
2023-07-270
OAAI
Hybrid and vaccine-induced immunity against SAR-CoV-2 in MS patients on different disease-modifying therapies
2022-09-2711
OA
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd-4th, 2021, Italy)

黑色素瘤的观点: 黑色素瘤桥会议报告 (意大利2021年12月2至4日)

2022-09-042
OAAI
Cellular and Humoral Immunity to SARS-CoV-2 Infection in Multiple Sclerosis Patients on Ocrelizumab and Other Disease-Modifying Therapies: A Multi-Ethnic Observational Study
2022-04-0122
OAAI
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 3rd-5th, 2020, Italy)

黑色素瘤的观点: 黑色素瘤桥会议报告 (意大利2020年12月3至5日)

2021-06-301
OAAI
Serial single-cell profiling analysis of metastatic TNBC during Nab-paclitaxel and pembrolizumab treatment

Nab-紫杉醇和pembrolizumab治疗期间转移性TNBC的系列单细胞分析

2020-09-1920
OAAI